PF 4856884

Drug Profile

PF 4856884

Alternative Names: CovX 060; CVX-060; PF-04856884; PF-4856884

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator CovX
  • Developer Pfizer
  • Class Antineoplastics; Peptides
  • Mechanism of Action Angiopoietin-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Renal cancer; Solid tumours

Most Recent Events

  • 09 May 2013 Discontinued - Phase-I/II for Solid tumours in USA (IV)
  • 09 May 2013 Discontinued - Phase-II for Renal cancer in USA (IV)
  • 06 Nov 2012 Pfizer terminates Phase-II trial in Renal cancer (combination therapy) in USA (NCT01441414)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top